Structure via PubChem · Public domain (PubChem)
indacaterol
Sign in to saveAlso known as QAB149, QAB-149, QAB 149, 5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered through a dry powder inhaler.
Chemical data
- Formula
- C24H28N2O3
- Molecular weight
- 392.5 g/mol
- IUPAC name
- 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
- SMILES
- CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
- InChIKey
- QZZUEBNBZAPZLX-QFIPXVFZSA-N
- XLogP
- 3.3
- Polar surface area
- 81.6 Ų
- H-bond donors
- 4
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Research
630 papers- Indacaterol.2006
- Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.The New England journal of medicine · 2016
- Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.Drugs · 2021
- Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma.Expert review of respiratory medicine · 2022
- Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.American journal of respiratory and critical care medicine · 2018
via PubMed
Wikidata facts
- Mass
- 392.209993
Show 6 more facts
- chemical formula
- C₂₄H₂₈N₂O₃
- Commons category
- Indacaterol
- canonical SMILES
- CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
- isomeric SMILES
- CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
- World Health Organisation international non-proprietary name
- indacaterol
- defined daily dose
- 0.15
Sources (7)
via Wikidata · CC0
~1 min read
Article
3 sectionsContents
- Medical uses
- History
- References
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered through a dry powder inhaler.
==Medical uses== A Cochrane review found benefit in lung function in people with COPD at least as good as that seen with twice-daily long-acting beta2-agonists. {| class="wikitable floatright" |+Receptor binding affinities (Ki) [nM] !Receptor !Ki |- |β1 |6.21 |- |β2 |7.36 |- |β3 |5.48 |}